| Company | 介绍 | Intro |
| Elpis Biopharmaceuticals | Elpis是一家正处于研发阶段的肿瘤免疫学公司，致力于通过精确调节免疫细胞的激活来开发下一代多功能癌症免疫治疗药物。我们已经建立了一个广泛的产品组合，包括双靶向CAR-T，免疫调节剂以及双特异性抗体。 | Elpis is an IND stage I/O company focus on developing next generation multi-functional cancer Immunotherapeutics through precision modulation of immune cell activation. We have built a broad portfolio that consists of multiple therapeutic modalities enabled by Elpis proprietary technology. |
| Pieris Pharmaceuticals | Pieris是一家临床阶段的生物技术公司，致力于将领先的蛋白质工程能力和对疾病分子驱动因素的深刻见解相结合。其基于人类脂质运载蛋白的专有 Anticalin 技术——天然结合并在全身运输分子的蛋白质——构成了我们开发重点的基础，以实现解决癌症和呼吸系统疾病的局部作用机制。其产品已在临床和与领先制药公司的合作中得到验证。 | Pieris is a clinical stage biotech company dedicated in combining leading protein engineering capabilities and deep insights into molecular drivers of disease. Their proprietary Anticalin technology based on human lipocalins – proteins that naturally bind and transport molecules throughout the body – forms the basis of our development focus to effect a local mechanism of action to address cancer and respiratory diseases. Their biologics have been validated in the clinic and by partnerships with leading pharmaceutical companies. |
| Biocytogen | 百奥赛图（北京）医药科技股份有限公司是一家全球性的生物技术公司，以创新技术推动新型抗体药物的研究和开发。百奥赛图拥有专有的全人抗体RenMice平台，进行单抗和双抗开发。百奥赛图的项目Project Integrum，对1000多个潜在可成药的靶点进行规模化药物开发，并与全球数十家合作伙伴达成持续合作，以生产各种FIC/BIC抗体药物。公司的管线包括12个核心产品，其中YH003是治疗胰腺导管腺癌和黑色素瘤的抗体，目前处于临床2期实验。 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company’s pipeline includes 12 core products, YH003 is an antibody for the treatment of PDAC and melanoma and is in clinical phase 2 trials. |
| Biosion | 博奥信是一家全球化具备自主研发能力的生物技术公司，致力于开发基于抗体药物的创新疗法，使患者在免疫及肿瘤疾病的治疗中获益。公司成立于2017年，博奥信通过内部专有的H³（高通量，高含量，高效率）抗体发现平台、SynTracer ADC抗体内吞筛选平台、以及Flexibody双特异抗体技术平台建立了一系列创新药物管线。其中自研产品BSI-045B（抗TSLP单抗）已针对特应性皮炎与重度哮喘开展全球I期临床试验，多项在研产品预计将于2022年进入临床阶段。博奥信在中国，美国与澳大利亚均设有分支机构。 | Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer HT-endocytosis and Flexibody bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. |
| Lipac Oncology | Lipac Oncology 是一家临床阶段的肿瘤制药公司。该公司主要利用其Lipax新型脂质体递送平台开发囊腔内肿瘤治疗药物。 标的资产是首款用于治疗非肌层浸润性膀胱 癌（ N MIBC ）的膀胱局部递送紫杉醇制剂。其递送技术可使药物灌注后保持在治疗浓度以上48小时。与现有化疗药物相比，标的资产膀胱灌注诱导的无复发生存率显著提升（ 83% vs 49% 49%）。目前，2b/3 临床试验方案已获得 FDA 批准。 | Lipac Oncology is a clinical stage oncology company leveraging its propriety LiPax™ liposomal drug delivery system to target intracavitary cancers with an initial focus on Non-muscle invasive bladder cancer (NMIBC). Two-year recurrence free survival rates of 83% in Phase 1/2a compares to 49% for current Soc FDA agreement on Phase 2b and Phase 3 placebo-controlled trial for Low/Int Risk NMIBC (expected start date of Q1 2024), n=182 |
| Duality Biologics | 映恩生物专注于肿瘤和自身免疫性疾病，已经建立了一个新颖的产品管线，包括10多个BIC/FIC的双特异性抗体和抗体偶联药物（ADC）。映恩生物已成功建立了具有全球知识产权的下一代ADC平台：DITAC（毒素）、DISAC（免疫刺激剂）和DIMAC（免疫抑制剂）。与目前领先的ADC技术平台相比，映恩生物的ADC平台（DITAC）选择性地向肿瘤组织释放有效载荷、肿瘤微环境浸润和卓越的系统稳定性方面具有显著优势。 | Focusing on the oncology and autoimmune diseases，Duality Biologics has built a novel pipeline including more than 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs. Duality Bio has successfully built the next-generation ADC platforms with global intellectual property rights – DITAC (toxin), DISAC (immune stimulator) and DIMAC (immune suppressor). Compared with the current leading ADC technology platform, Duality Bio’s toxin ADC platform (DITAC) offers significant advantages in terms of tumor selective payload release, tumor microenvironment infiltration and superior systemic stability. |
| Dartsbio Pharmaceuticals | 达石药业是一家创新型抗体药物与药物偶联体研发商，专注于肿瘤、免疫和镇痛等领域达。达石药业的核心科技是抗体发现、抗体分子工程改造与新一代抗体人源化，运用此技术平台，辐射至单克隆抗体药物、双特异性抗体药物与抗体偶联药物（ADC）等领域的抗体药物开发。DS002是达石药业所开发的一种靶向神经生长因子（NGF）的人源化重组单克隆抗体，在慢性疼痛和化疗药引起的疼痛等适应症中，具有取代阿片类和 NSAIDs 药物的潜力,2021年进入处于临床I 期阶段。 | Dasher Pharmaceuticals is an developer of antibody drugs and ADC, focusing on oncology, immunology and analgesia. Our core technologies are antibody discovery, antibody molecular engineering and next-generation antibody humanization, which are used to develop antibody drugs in the areas of monoclonal antibody drugs, bispecific antibody drugs and antibody-coupled drugs (ADCs). DS002 is a humanised recombinant monoclonal antibody targeting Nerve Growth Factor (NGF) developed by Dazed Pharmaceuticals, which blocks the binding of NGF to TrkA on the surface of injurious receptors by binding to NGF, resulting in non-addictive and potent analgesia. It has the potential to replace opioids and NSAIDs in indications such as chronic pain and pain caused by chemotherapeutic agents. |
| ITabMed | 天劢源和生物医药(上海)有限公司是一家生物技术公司，专注于肿瘤免疫治疗的创新药物研发。我们建立和优化了免疫治疗抗体技术平台 (iTAbTM)，并拥有一系列国内国际专利。该技术平台利用T细胞衔接器 ( T cell engager)原理，开发双特异性和多特异性抗体（A-319、A-337）。 | ITabMed Ltd. is a biotechnology company focused on the development of innovative drugs for tumour immunotherapy. We have been building and optimizing an immunotherapy antibody (iTAbTM) platform with a series of granted patents. The platform applies the mechanism of T-cell engager (TCE) to generate T cell activating bi- or tri-specific iTAb antibody(A-319，A-337). |
| CARsgen Therapeutics | 科济药业控股有限公司是一家主要从事创新嵌合抗原受体（CAR）T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。该公司已开发升级版靶向 B 细胞成熟抗原（BCMA）的 CAR-T 产品 CT053。CT053 为其的唯一核心候选产品。该公司在中国和美国开展业务。 | CARsgen Therapeutics is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. Our product pipeline include an upgraded clinical stage fully-human BCMA CAR-T (CT053), globally potential first-in-class Claudin18.2 CAR-T (CT041) with the only IND clearance, and the globally potential first-in-class GPC3 CAR-T (CT011) is in phase I. |
| Activate Therapeutics | Activate Therapeutics是Immunova LLC的肿瘤业务分支机构。Activate使用其专有的纳米技术，即 “Nanolipogels”，来加强免疫疗法的治疗，目的是通过激活免疫系统，提高癌症患者的反应率和持久性。Activate公司核心资产ACT-1是一款TLR7激动剂和IL-2长效缓释脂质体制剂，目前处于pre-ind 阶段。 | Activate Therapeutics is the operating oncology affiliate of Immunova LLC. Activate uses its proprietary nanotechnology, called “Nanolipogels”, to enhance immunotherapy treatments with the aim of increasing both the response rate, and durability in cancer patients by activating both the innate and adaptive arms of the immune system. Activate’s lead asset ACT-1 is a pre-ind stage long acting sustained release liposomal formulation of TLR7 agonist and IL-2. |
| Anjie Broad: Keynote Speech on Legislative Trends about Licensing-in Transactions (in Chinese) | 安杰律师事务所 2012 年由一批拥有共同理念、具备团队精神、丰富执业经验及法律专业特长的资深律师倡议设立。安杰采取一体化的管理模式，倡导客户至上、专业精进、品质控制及资源共享。安杰坚持统一的法律服务标准，实行规范的客户服务体系， 致力于为客户提供优质高效和量身定制的法律服务 |
Oncology – June 21 | Summer showcase 2022
BioToChina.org 